Intestinal Perforation in Colorectal Cancers Treated with Bevacizumab (Avastin(R)) / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 33-35, 2008.
Artículo
en Inglés
| WPRIM
| ID: wpr-65926
ABSTRACT
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in which the patients suffered from intestinal perforation after chemotherapy with bevacizumab. For the first case, a 47 year-old man had rectal cancer with concurrent liver and lung metastasis. He underwent chmotherapy with 5-fluorouracil, irinotecan and bevacizumab. Fever and abdominal pain developed seven days later, and rectal perforation was identified upon exploration 13 days later. For the second case, a 48 year-old woman had sigmoid colon cancer with peritoneal and ovary metastases. After seven days of chemotherapy with 5-fluorouracil, oxaliplatin and bevacizumab, exploratory surgery revealed a perforation at the ileum.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Compuestos Organoplatinos
/
Ovario
/
Neoplasias del Recto
/
Neoplasias del Colon Sigmoide
/
Camptotecina
/
Neoplasias Colorrectales
/
Dolor Abdominal
/
Factor A de Crecimiento Endotelial Vascular
/
Fiebre
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Estudio pronóstico
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS